Published online before print May 5, 2005, doi: 10.1161/01.STR.0000166048.35740.a9
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:1218.)
© 2005 American Heart Association, Inc.
Original Contributions |
Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention
Principal Results of a Prospective Randomized Controlled Study (MOSES)
From the Department of Internal Medicine (J.S., S.L., A.K., F.H.), St. Josefs Hospital, Cloppenburg, Germany; Institute for Hypertension and Cardiovascular Research (K.P.), Cloppenburg, Germany; Medical Biometry and Epidemiology (J.B.), University Hospital Hamburg-Eppendorf, Germany; Department of Nephrology (W.Z.), Charité Campus Benjamin Franklin, Berlin, Germany; Department of Pharmacology and Toxicology (P.D.), University of Lübeck, Germany; and Department of Neurology (H.C.D.), University of Essen, Germany.
Correspondence to Dr Stephan Lüders, Medizinische Klinik, St. Josefs Hospital, Krankenhausstr. 13, 49661 Cloppenburg, Germany. E-mail s.lueders{at}kh-clp.de
Background and Purpose— In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality.
Methods— A total of 1405 well-defined, high-risk hypertensives with cerebral event during the last 24 months (proven by cerebral computed tomography scan or nuclear magnetic resonance) were randomized to eprosartan or nitrendipine (mean follow-up 2.5 years). Primary end point was the composite of total mortality and all cardiovascular and cerebrovascular events, including all recurrent events.
Results— Randomization was successful without significant differences in the baseline characteristics. Blood pressure was reduced to a comparable extent without any significant differences between the 2 groups during the whole study period (150.7/84 mm Hg and 152.0/87.2 mm Hg with eprosartan and nitrendipine therapy to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively, confirmed by ambulatory blood pressure monitoring). Moreover, already after 3 months, normotensive mean values were achieved, and 75.5% reached values <140/90 mm Hg with the eprosartan regimen and 77.7% with the nitrendipine regimen. During follow-up, in total, 461 primary events occurred: 206 eprosartan and 255 nitrendipine (incidence density ratio [IDR], 0.79; 95% CI, 0.66 to 0.96; P=0.014). Cardiovascular events were: 77 eprosartan and 101 nitrendipine (IDR, 0.75; 95% CI, 0.55 to 1.02; P=0.06); cerebrovascular events: 102 eprosartan and134 nitrendipine (IDR, 0.75; 95% CI, 0.58 to 0.97; P=0.03).
Conclusions— The Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention (MOSES) study was the first to compare an angiotensin II type 1 receptor antagonist with a calcium antagonist in secondary stroke prevention. In these high-risk hypertensive stroke patients, an early normotensive and comparable blood pressure was achieved. The combined primary end point was significantly lower in the eprosartan group.
Key Words: eprosartan • hypertension • nitrendipine • stroke prevention
Related Article:
Stroke 2005 36: 1225-1226.
This article has been cited by other articles:
 |
|
 |
|
  M. H. Strauss and A. Hall Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No Stroke, September 1, 2009; 40(9): 3161 - 3162. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Armario and A. de la Sierra Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents? Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 197 - 204. [Abstract] [PDF]
|
|
|
|
|
|
V. Aiyagari and P. B. Gorelick Management of Blood Pressure for Acute and Recurrent Stroke Stroke, June 1, 2009; 40(6): 2251 - 2256. [Full Text] [PDF]
|
|
|
|
|
|
G. T. McInnes Telmisartan to Prevent Recurrent Stroke: The PRoFESS Study: Was the Baby Thrown Out With the Bathwater? Stroke, May 1, 2009; 40(5): 1938 - 1940. [Full Text] [PDF]
|
|
|
|
|
|
S. Inaba, M. Iwai, Y. Tomono, I. Senba, M. Furuno, H. Kanno, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes Stroke, February 1, 2009; 40(2): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Inaba, M. Iwai, M. Furuno, Y. Tomono, H. Kanno, I. Senba, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice Hypertension, February 1, 2009; 53(2): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doumas, V. Papademetriou, J. Fichet, C. Bressolle, R. O. Fournier, J.-M. Achard, A. Fournier, S. Yusuf, H.-C. Diener, and R. L. Sacco Telmisartan for prevention of cardiovascular events. N. Engl. J. Med., January 15, 2009; 360(3): 302 - 303. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Diener, H. Mattle, M. Böhm, and F. Ruschitzka CHAPTER 15a The Heart and the Brain ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Turnbull, M. Woodward, B. Neal, F. Barzi, T. Ninomiya, J. Chalmers, V. Perkovic, N. Li, S. MacMahon, and the Blood Pressure Lowering Treatment Trialists' C Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials Eur. Heart J., November 1, 2008; 29(21): 2669 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yamamoto, N. Tamamaki, T. Nakamura, K. Kataoka, Y. Tokutomi, Y.-F. Dong, M. Fukuda, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama Excess Salt Causes Cerebral Neuronal Apoptosis and Inflammation in Stroke-Prone Hypertensive Rats Through Angiotensin II-Induced NADPH Oxidase Activation Stroke, November 1, 2008; 39(11): 3049 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Talelli and R. J. Greenwood Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 387 - 405. [Abstract] [PDF]
|
|
|
|
|
|
P. M.W. Bath, C. Geeganage, L. J. Gray, T. Collier, and S. Pocock Use of Ordinal Outcomes in Vascular Prevention Trials: Comparison With Binary Outcomes in Published Trials * Supplemental Appendix I: Statistical Tests Compared * Supplemental Appendix II: Supplementary Analyses * Supplemental Appendix III: Results Stroke, October 1, 2008; 39(10): 2817 - 2823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yusuf, H.-C. Diener, R. L. Sacco, D. Cotton, S. Ounpuu, W. A. Lawton, Y. Palesch, R. H. Martin, G. W. Albers, P. Bath, et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events N. Engl. J. Med., September 18, 2008; 359(12): 1225 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Iwanami, M. Mogi, J.-M. Li, K. Tsukuda, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Deletion of Angiotensin II Type 2 Receptor Attenuates Protective Effects of Bone Marrow Stromal Cell Treatment on Ischemia-Reperfusion Brain Injury in Mice * Supplemental Materials and Methods Stroke, September 1, 2008; 39(9): 2554 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Lopez-Jimenez, M. Camafort, G. Tiberio, J. A. Carmona, C. Guijarro, F. Martinez-Penalver, M. Monreal, and FRENA Investigators Secondary Prevention of Arterial Disease in Very Elderly People: Results From a Prospective Registry (FRENA) Angiology, August 1, 2008; 59(4): 427 - 434. [Abstract] [PDF]
|
|
|
|
|
|
J.-M. Li, M. Mogi, J. Iwanami, L.-J. Min, K. Tsukuda, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density Stroke, July 1, 2008; 39(7): 2029 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mancia and G. Grassi Editorial: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 5 - 12. [PDF]
|
|
|
|
|
|
T. Nakamura, E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan Hypertension, February 1, 2008; 51(2): 296 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Townsend Stroke in Chronic Kidney Disease: Prevention and Management Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S11 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsukuda, M. Mogi, J.-M. Li, J. Iwanami, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Amelioration of Cognitive Impairment in the Type-2 Diabetic Mouse by the Angiotensin II Type-1 Receptor Blocker Candesartan Hypertension, December 1, 2007; 50(6): 1099 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. U. Park and A. L. Taylor Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review Ann. Fam. Med, September 1, 2007; 5(5): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S Hall and M. H Strauss More about the "ARB MI paradox" Heart, September 1, 2007; 93(9): 1011 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Wang, Y. Li, S. S. Franklin, and M. Safar Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview Hypertension, July 1, 2007; 50(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Messerli Cerebroprotection by Hypertension in Ischemic Stroke: The Crumbling of a Hypothesis Circulation, June 12, 2007; 115(23): 2907 - 2908. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
A D Struthers Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients Heart, December 1, 2006; 92(12): 1728 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Oprisiu-Fournier, J.-M. Serot, J.-M. Achard, F. H. Messerli, S. E. Black, and A. Fournier AT1 Receptor Blockers for Cognition Decline After Cardiac Surgery? Stroke, November 1, 2006; 37(11): 2666 - 2666. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Williams The Year in Hypertension J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1698 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Tsuyuki and M. A. McDonald Response to Tsuyuki and McDonald Circulation, August 22, 2006; 114(8): 855 - 860. [Full Text] [PDF]
|
|
|
|
|
|
P. M.W. Bath and N. Sprigg Control of Blood Pressure After Stroke Hypertension, August 1, 2006; 48(2): 203 - 204. [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, L. Thijs, and J. A. Staessen Blood Pressure Lowering for Primary and Secondary Prevention of Stroke Hypertension, August 1, 2006; 48(2): 187 - 195. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sever, N. R. Poulter, W. J. Elliott, M. C. Jonsson, H. R. Black, P. S. Sever, N. R. Poulter, W. J. Elliott, M. C. Jonsson, and H. R. Black Blood Pressure Reduction Is Not the Only Determinant of Outcome Circulation, June 13, 2006; 113(23): 2754 - 2774. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Poulter, A. D Hughes, B. Williams, A. J. Brady, and G. McInnes Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: A mini-symposium held at the British Hypertension Society Meeting, September 2005 Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 104 - 121. [PDF]
|
|
|
|
|
|
J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, and H. C. Diener Response to Letter by Larsen et al Stroke, June 1, 2006; 37(6): 1358 - 1358. [Full Text] [PDF]
|
|
|
|
|
|
K. Larsen, N. Hornnes, and G. Boysen Does the MOSES Study Provide Sufficient Evidence for Eprosartan Against Nitrendipine? Stroke, June 1, 2006; 37(6): 1357 - 1357. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Segura, J. A. Garcia-Donaire, M. Praga, and L. M. Ruilope Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S136 - S140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Flack Noninvasive Hemodynamic Measurements: An Important Advance in Individualizing Drug Therapies for Hypertensive Patients Hypertension, April 1, 2006; 47(4): 646 - 647. [Full Text] [PDF]
|
|
|
|
|
|
A. Fournier, G. Choukroun, S. S. Modeliar, O. Godefroy, J.-M. Achard, J. Wang, and F. Messerli Does the MOSES Trial Establish Superiority of AT1-Receptor Blockers Over Dihydropyridine/Calcium Antagonists in Secondary Stroke Prevention? Stroke, February 1, 2006; 37(2): 336 - 337. [Full Text] [PDF]
|
|
|
|
|
|
A. Owen, J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, H. C. Diener, et al. MOSES: Superiority or Noninferiority? * Response: Stroke, February 1, 2006; 37(2): 337 - 338. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Strauss, S. Verma, J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, et al. MOSES Raises Questions * Response: Stroke, February 1, 2006; 37(2): 338 - 340. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein and G. J. Hankey Advances in Primary Stroke Prevention Stroke, February 1, 2006; 37(2): 317 - 319. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Boulanger and M. D. Hill Morbidity and Mortality After Stroke--Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) Stroke, February 1, 2006; 37(2): 335 - 336. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., December 1, 2005; 10(6): 191 - 192. [Full Text] [PDF]
|
|
|
|
|
|
S. Nathan, C. J. Pepine, and G. L. Bakris Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients Hypertension, October 1, 2005; 46(4): 637 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Strandberg Editorial Comment: Secondary Prevention of Stroke Is Important: But All Hypertensive Drugs Are Not Created Equal? Stroke, June 1, 2005; 36(6): 1225 - 1226. [Full Text] [PDF]
|
|